1. Why CKD evaluation uses both eGFR and urine albumin

Chronic kidney disease (CKD) is an abnormality of kidney structure or function that has implications for health and is present for at least 3 months. KDIGO classifies CKD by cause, glomerular filtration rate (GFR), and albuminuria (the CGA framework). Estimated GFR (eGFR), commonly calculated from blood creatinine, describes filtration; the urine albumin-to-creatinine ratio (uACR) helps identify kidney damage and refine risk. Neither result alone describes every person’s kidney health.

NIDDK explains that clinicians use a blood test for GFR and a urine test for albumin to check and monitor kidney disease. Creatinine comes from normal muscle breakdown, so individual characteristics and clinical context can affect how an estimate is interpreted. When creatinine-based eGFR may be less accurate or a more precise assessment is needed, clinicians may consider cystatin C and other evaluation. These tests support clinical assessment; they are not a self-diagnosis from one laboratory value.

2. KDIGO GFR and albuminuria categories

The KDIGO 2024 adult GFR categories are G1 (at least 90), G2 (60–89), G3a (45–59), G3b (30–44), G4 (15–29), and G5 (below 15) mL/min/1.73 m². Albumin-to-creatinine ratio (ACR) categories are A1 (below 30 mg/g), A2 (30–300 mg/g), and A3 (above 300 mg/g), described respectively as normal to mildly increased, moderately increased, and severely increased. These are classification ranges that help organize risk assessment; they do not by themselves predict an individual outcome.

An eGFR in G1 or G2, without another marker of kidney damage, does not meet the CKD criteria by itself. Likewise, a single eGFR below 60 or ACR at or above 30 mg/g needs interpretation in the context of persistence and other clinical information. Reading GFR and albuminuria together is more informative than treating either as a complete diagnosis. The older label “microalbuminuria” can obscure the current A1–A3 classification, so this article uses the KDIGO categories.

3. Persistence, repeat testing, and measurement limits

One low eGFR or elevated uACR does not establish chronic kidney disease. The KDIGO definition requires an abnormality to be present for at least 3 months, but this does not mean every person should wait 90 days before any reassessment. If acute kidney injury or another urgent change is possible, clinicians may evaluate sooner. The KDIGO adult screening algorithm says retesting time should be based on individual characteristics.

Urine albumin can vary with temporary conditions, including infection, fever, or exercise. NIDDK’s patient information says a urine albumin test may be repeated one or two more times to confirm an abnormal result; the timing and additional tests depend on the person’s circumstances. Laboratory reference ranges and the broader clinical picture also matter. People with risk factors such as diabetes or high blood pressure can discuss whether and how often testing is appropriate with their care team.

4. Expert perspective: institutional guidance and its limits

KDIGO 2024 recommends assessing GFR and albuminuria together, while considering the cause of kidney disease and the person’s context. This approach avoids assigning a diagnosis from eGFR alone or treating one test as a complete risk assessment. Risk varies across GFR and albuminuria categories and by cause; clinicians may select further tests and follow-up accordingly. KDIGO describes its guideline as evidence-based decision support, not an exclusive course of management for every individual.

Source note: KDIGO 2024 is an institutional clinical practice guideline, and the NIDDK page is institutional patient information about testing and diagnosis. Their institutional guidance is summarized here; no named person’s opinion is attributed.

References and Source Links